FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for KEPPRA (levetiracetam) from UCB, Inc., potentially expanding labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Tonic-clonic Seizures
• Juvenile Myoclonic Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Keppra (levetiracetam)

Snippet

SUPPL AP for KEPPRA (LEVETIRACETAM)